BZYR BURZYNSKI RESEARCH INSTITUTE INC

OTC In Vitro & In Vivo Diagnostic Substances DE CIK: 0000724445
AI RATING
STRONG_SELL
95% Confidence

Investment Thesis

Burzynski Research Institute is in critical financial distress with zero revenue, massive operating losses, severely depleted assets ($2.3K), and negative stockholders equity of -$67.3K. The company is technically insolvent with liabilities exceeding assets by $67.3K and insufficient cash ($2.2K) to support ongoing operations, making recovery highly unlikely.

Strengths

Risks

  • ! Zero revenue generation - complete loss of business operations
  • ! Negative stockholders equity of -$67.3K indicates technical insolvency
  • ! Massive liquidity crisis with current ratio of 0.05x and only $2.2K in cash
  • ! Operating and free cash flows deeply negative at -$967.2K
  • ! Total liabilities ($69.6K) far exceed total assets ($2.3K) by 30x
  • ! Extreme negative ROA of -43893.2% indicates severe asset impairment
  • ! No insider buying activity suggests loss of management confidence
  • ! Inadequate working capital to support basic operations or debt service

Key Metrics to Watch

Financial Metrics

Revenue
0.0
Net Income
-994.2K
EPS (Diluted)
$-0.01
Free Cash Flow
-967.2K
Total Assets
2.3K
Cash
2.2K

Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA -43,893.2%
FCF Margin N/A

Balance Sheet & Liquidity

Current Ratio
0.05x
Quick Ratio
0.05x
Debt/Equity
N/A
Debt/Assets
3,073.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-03-21T20:26:10.238196 | Data as of: 2025-11-30 | Powered by Claude AI